Paper41536985
SLC39A10 drives M2 macrophage polarization and gastric cancer progression through the MAPK14(p38α) pathway.
Liang Y and 6 others. iScience, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. SLC39A10 drives M2 macrophage polarization and gastric cancer progression through the MAPK14(p38α) pathway. Papers, record 41536985. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41536985
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- SLC39A10 drives M2 macrophage polarization and gastric cancer progression through the MAPK14(p38α) pathway.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29324807 | VEGF may contribute to macrophage recruitment and M2 polarization in the decidua. | PLoS One | 2018 | https://conductscience.org/library/papers/29324807 | PubMed |
| 2 | 38339430 | Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know? | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38339430 | PubMed |
| 3 | 37211559 | Macrophages in immunoregulation and therapeutics. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/37211559 | PubMed |
| 4 | 36139403 | Targeting Gastric Cancer Stem Cells to Enhance Treatment Response. | Cells | 2022 | https://conductscience.org/library/papers/36139403 | PubMed |
| 5 | 29180421 | Metal transporter Slc39a10 regulates susceptibility to inflammatory stimuli by controlling macrophage survival. | Proc Natl Acad Sci U S A | 2017 | https://conductscience.org/library/papers/29180421 | PubMed |
| 6 | 31845513 | The Interaction of Sodium and Zinc in the Priming of T Cell Subpopulations Regarding Th17 and Treg Cells. | Mol Nutr Food Res | 2020 | https://conductscience.org/library/papers/31845513 | PubMed |
| 7 | 38459596 | Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression. | Mol Cancer | 2024 | https://conductscience.org/library/papers/38459596 | PubMed |
| 8 | 36078080 | TcpC Inhibits M1 but Promotes M2 Macrophage Polarization via Regulation of the MAPK/NF-κB and Akt/STAT6 Pathways in Urinary Tract Infection. | Cells | 2022 | https://conductscience.org/library/papers/36078080 | PubMed |
| 9 | 35141222 | Mapk14 is a Prognostic Biomarker and Correlates with the Clinicopathological Features and Immune Infiltration of Colorectal Cancer. | Front Cell Dev Biol | 2022 | https://conductscience.org/library/papers/35141222 | PubMed |
| 10 | 37245017 | Gastric cancer treatment: recent progress and future perspectives. | J Hematol Oncol | 2023 | https://conductscience.org/library/papers/37245017 | PubMed |
| 11 | 38542354 | Gastric Cancer in the Era of Epigenetics. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38542354 | PubMed |
| 12 | 37032648 | Paeonol alleviates neuropathic pain by modulating microglial M1 and M2 polarization via the RhoA/p38MAPK signaling pathway. | CNS Neurosci Ther | 2023 | https://conductscience.org/library/papers/37032648 | PubMed |
| 13 | 34395329 | SLC39A10 Upregulation Predicts Poor Prognosis, Promotes Proliferation and Migration, and Correlates with Immune Infiltration in Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2021 | https://conductscience.org/library/papers/34395329 | PubMed |
| 14 | 37548941 | Mesenchymal Stem Cell-Derived Exosomes Promote Recovery of The Facial Nerve Injury through Regulating Macrophage M1 and M2 Polarization by Targeting the P38 MAPK/NF-Κb Pathway. | Aging Dis | 2024 | https://conductscience.org/library/papers/37548941 | PubMed |
| 15 | 28449873 | Progress in tumor-associated macrophage (TAM)-targeted therapeutics. | Adv Drug Deliv Rev | 2017 | https://conductscience.org/library/papers/28449873 | PubMed |
| 16 | 36936929 | Identification of lactylation related model to predict prognostic, tumor infiltrating immunocytes and response of immunotherapy in gastric cancer. | Front Immunol | 2023 | https://conductscience.org/library/papers/36936929 | PubMed |
| 17 | 30718830 | Macrophages as regulators of tumour immunity and immunotherapy. | Nat Rev Immunol | 2019 | https://conductscience.org/library/papers/30718830 | PubMed |
| 18 | 37524874 | SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK/ERK and PI3K/AKT pathways. | Exp Mol Med | 2023 | https://conductscience.org/library/papers/37524874 | PubMed |
| 19 | 32626961 | SB203580 protects against inflammatory response and lung injury in a mouse model of lipopolysaccharide‑induced acute lung injury. | Mol Med Rep | 2020 | https://conductscience.org/library/papers/32626961 | PubMed |
| 20 | 25074919 | Zinc transporter SLC39A10/ZIP10 controls humoral immunity by modulating B-cell receptor signal strength. | Proc Natl Acad Sci U S A | 2014 | https://conductscience.org/library/papers/25074919 | PubMed |
Genes35
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41536985
GET https://conductscience.org/api/papers/v1/41536985/references?page=2